Option chain shows key data for VYNE Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for VYNE Therapeutics.

VYNE Therapeutics (NASDAQ:VYNE) Stock, Option Chain

VYNE Therapeutics

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.

Long Ideas

News

Penny Stocks

Pre-Market Outlook

Markets

Trading Ideas

ALVR

ALPS ETF Trusthen & Steers Global Realty Majors ETF

IBIO

VYNE

The most oversold stocks in the health care presents an opportunity to buy into undervalued companies.

Top 4 Health Care Stocks That May Rocket Higher In Q1

Small Cap

Movers

ATNF

BCEL

BTCS

CMND

FTFT

GBNH

OCTO

PAVM

Qualigen Therapeutics, Inc. - Common Stock

QLGN

RDZN

RELL

SDIG

SPEC

TGAN

XCUR

Shares of  Richardson Electronics, Ltd.  (NASDAQ: RELL) fell sharply in today’s pre-market trading after the company posted weaker-than-expected results for its second quarter.

Why Richardson Electronics Shares Are Trading Lower By 13%; Here Are 20 Stocks Moving Premarket

Earnings

Eurozone

Commodities

Global

Intraday Update

ALZN

COMM

LMDX

MIRO

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 500 points on Monday.

The Dow traded up 1.67% to 32,959.68 while the NASDAQ rose 1.25% to 12,800.95. The S&amp;P 500 also rose, gaining, 1.23% to 4,167.91.

Dow Surges Over 500 Points; Western Digital Announces Plan To Split Into Two Companies

VYNE Therapeutics Inc

Management

Press Releases

VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development

Health Care

Legal

VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor

VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

VYNE Therapeutics to Participate in September Investor Conferences

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

Analyst Ratings

VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

VYNE Therapeutics to Participate in March Investor Conferences

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

AN2 Therapeutics

CalciMedica

Cara Therapeutics

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Durect

Grace Therapeutics

Impact BioMedical

IGC Pharma

Ikena Oncology

Opus Genetics

Iterum Therapeutics

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Lexaria Bioscience

NRX Pharmaceuticals

OptiNose

Pulmatrix

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Scilex Holding

SCYNEXIS

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals

HC Wainwright & Co.

BTIG

Cantor Fitzgerald

Comments

VYNE Therapeutics

VYNE Therapeutics (VYNE) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga